Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm;Tratamiento del dolor óseo metastásico con dosis repetidas de estroncio-89 en pacientes con neoplasia de prótata

Revista Espanola de Medicina Nuclear

Volumn 19, Issue 4, 2000, Pages 270-274

  Fuster, D ^a   Herranz, R ^a   Alcover, J ^a   Mateos, J J ^a   Martin F ^a   Vidal Sicart, S ^a   Pons, F ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Bone metastases; Prostate cancer; Strontium 89

Indexed keywords

STRONTIUM 89; STRONTIUM; STRONTIUM CHLORIDE;

AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER THERAPY; CLINICAL ARTICLE; DRUG EFFECT; HUMAN; KARNOFSKY PERFORMANCE STATUS; PROSTATE TUMOR; REPEATED DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BLOOD; BONE TUMOR; CLINICAL TRIAL; MALE; METASTASIS; PAIN; PATHOLOGY;

AGED; BONE NEOPLASMS; HUMANS; MALE; PAIN; PROSTATIC NEOPLASMS; STRONTIUM;

EID: 0034242167     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/s0212-6982(00)71874-x     Document Type: Article

References (16)

1. Robinson RG, Preston DF, Spicer JA, Baxter KG. Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med 1992;22:28-32.
2. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991;9:509-24.
3. Robinson RG, Preston DF, Baxter KG, Dusing RW, Spicer JA. Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin Oncol 1993;20(Supl 2):44-8.
4. McEwan AJB, Porter AT, Venner PM, Amyotte G. An evaluation of the safety and efficacy of treatment with strontium-89 in patients who had previously received wide field radiotherapy. Antibody Immunoconj Radiopharm 1990;3:91-8.
5. Quilty PM, Kirk D, Bolger JJ, Dearbaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40.
6. Pons F, Herranz R, García A, Vidal-Sicart S, Conill C, Grau JJ, et al. Strontium-89 palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 1997;24:1210-4.
7. Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998;25:1362-7.
8. Blake GM, Zivanovic MA, McEwan Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986;12:447-54.
9. Ben-Josef E, Lucas DR, Vasan S, Porter AT. Selective accumulation of strontium-89 in metastatic deposits in bone: radiohistological correlation. Nucl Med Commun 1995;16:457-63.
10. Bree SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy in metastatic prostatic carcinoma. J Nucl Med 1992;33:1316-23.
11. 89Sr-chloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun 1994;15:499-504.
12. Laing AH, Ackery DM, Baily RJ. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991;64:816-22.
13. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
14. Robinson RG, Blake GM, Preston DF, McEwan AJ, Spicer JA, Martin NL, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989;9:271-81.
15. Berna L, Carrió I, Alonso C, Ferré J, Estorch M, Torres G. Bone palliation with strontium-89in breast cancer patients with bone metastases and refractory bone pain. Eur J Nucl Med 1995;22:1101-4.
16. Lee CK, Aeppli DM, Unger J, Boudreau RJ, Levitt SH. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases: the University of Minnesota experience. Am J Clin Oncol Cancer Clin Trails 1996;19:102-7.